Patents by Inventor Chea Ha Kim

Chea Ha Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION FOR CULTURING REGULATORY T CELLS AND USE THEREOF
    Publication number: 20230407253
    Abstract: The present invention relates to a method for effectively proliferating regulatory T cells, by which, particularly, in the presence of a fusion protein dimer comprising IL-2. protein or a variant thereof and CD80 protein or a fragment thereof, CD4+, CD25+, and CD127? T cells can be effectively proliferated. In particular, when combined with a predetermined cell culture medium, regulatory T cells such as CD4+, CD25+, and CD127? can be effectively and specifically proliferated. In addition, when the method is used, it has been confirmed that the survival rate of regulatory T cells is remarkably increased as compared to a conventionally used culture method using IL-2, and a significant increase in the yield of Foxp3+ regulatory T cells has been confirmed. Thus, such a proliferation method can be used in the field of cell therapeutic agents using regulatory T cells.
    Type: Application
    Filed: May 15, 2023
    Publication date: December 21, 2023
    Inventors: Myoung Ho JANG, Chun-Pyo HONG, Chea Ha KIM, Hye Ri KIM
  • Composition for culturing regulatory T cells and use thereof
    Patent number: 11702633
    Abstract: The present invention relates to a method for effectively proliferating regulatory T cells, by which, particularly, in the presence of a fusion protein dimer comprising IL-2 protein or a variant thereof and CD80 protein or a fragment thereof, CD4+, CD25+, and CD127? T cells can be effectively proliferated. In particular, when combined with a predetermined cell culture medium, regulatory T cells such as CD4+, CD25+, and CD127? can be effectively and specifically proliferated. In addition, when the method is used, it has been confirmed that the survival rate of regulatory T cells is remarkably increased as compared to a conventionally used culture method using IL-2, and a significant increase in the yield of Foxp3+ regulatory T cells has been confirmed. Thus, such a proliferation method can be used in the field of cell therapeutic agents using regulatory T cells.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: July 18, 2023
    Assignee: GI CELL, INC.
    Inventors: Myoung Ho Jang, Chun-Pyo Hong, Chea Ha Kim, Hye Ri Kim